Outcome analysis of localized gastrointestinal lymphoma treated with surgery and postoperative irradiation.
One hundred thirteen patients with localized gastrointestinal lymphoma treated by surgery and postoperative irradiation between 1967 and 1985 were reviewed. At 15 years, actuarial survival of this group was 40.6%, with a cause-specific survival of 69.2% and a relapse-free rate of 64%. Two-thirds of relapses occurred at distant sites. In Stage IA and IIA patients with no residuum or with positive resection margins, (N = 90) only site of involvement and stage predicted for relapse. Age, histologic subtype group, and depth of bowel wall invasion did not affect relapse risk. In the very favorable group (Stage IA, IIA, no residuum or microscopic residuum), 8.4% of patients with stomach lymphoma relapsed compared to 25% of patients with small bowel lymphoma. The risk of early relapse was higher in those with Stage IIA small bowel lymphoma than those with Stage IA small bowel lymphoma. We continue to recommend adjuvant abdominal irradiation for patients with Stage IA, IIA completely resected stomach lymphoma and Stage IA completely resected small bowel lymphoma. We recommend combined modality therapy for patients with completely resected Stage IIA small bowel lymphoma and all other localized gastrointestinal lymphoma where visible residual disease is present.
Gospodarowicz
M K
MK
Department of Radiation Oncology, Princess Margaret Hospital, Toronto, Ontario, Canada.
Sutcliffe
S B
SB
Clark
R M
RM
Dembo
A J
AJ
Patterson
B J
BJ
Fitzpatrick
P J
PJ
Chua
T
T
Bush
R S
RS
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D003131:Combined Modality Therapy; D005770:Gastrointestinal Neoplasms / Q000628:therapy*; D006801:Humans; D008223:Lymphoma / Q000628:therapy*; D008875:Middle Aged; D009367:Neoplasm Staging; D010043:Outcome and Process Assessment, Health Care; D011379:Prognosis; D011879:Radiotherapy Dosage; D012008:Recurrence